Company: ARMP
Filing Date: 2025-05-19
Form Type: 8-K
Source: 0001104659-25-050219
Chunk: 0

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-05-19
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item 7.01      Regulation FD Disclosure.  

On May 19, 2025, Armata Pharmaceuticals, Inc. (the “ Company”)
issued a press release announcing positive topline data from the Phase 1b/2a diSArm study of intravenously administered AP-SA02 in complicated Staphylococcus aureusbacteremia. The full text of the press release issued in connection with this announcement is furnished as
Exhibit 99.1 to this Current Report on Form 8-K.

The Company posted an updated corporate presentation dated May 19,
2025 (the “ Corporate Presentation”) to its website at https://investor. armatapharma. com/events-and-presentations. The Corporate
Presentation, which is furnished as Exhibit 99.2 hereto, replaces the corporate presentation dated May 14, 2025 previously posted
to the Company’s website. The Company plans to use its website to disseminate future updates to the Corporate Presentation and may
not file or furnish a Current Report on Form 8-K alerting investors if the Corporate Presentation is updated.

The information contained in the Corporate Presentation is summary
information that is intended to be considered in the context of the Company’s Securities and Exchange Commission (“ SEC”)
filings and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes
no duty or obligation to publicly update or revise the information contained in this report, except as may be required by the federal
securities laws, although it may do so from time to time as its management believes is warranted. Any such updating may be made through
the filing of other reports or documents with the SEC, through press releases or through other public disclosure. In addition, the Company
disclaims any inferences regarding the materiality of such information that may arise as a result of it furnishing such information under
Item 7.01 of this Current Report on Form 8-K.

The information in this Item 7.01 and the attached Exhibits 99.1 and
99.2 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange
Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 7.01 and the attached Exhibits
99.1 and 99.2 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities